Fresh from the designation pipeline: orphan drugs recently designated in the European Union (June – August 2013)

Bibliography

• Sabina Antoniu. Fresh from the designation pipeline: orphan drugs recently designated in the European Union (November 2012 – January 2013). Expert Opin Orphan Drugs 2013;1(6):499-505
   Web of Science ®Google Scholar
• Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet 2006;368(9549):1795-809
   PubMed Web of Science ®Google Scholar
• Tawada A, Sugawara T, Ogata K, et al. Improvement of central retinal sensitivity six months after topical isopropyl unoprostone in patients with retinitis pigmentosa. Indian J Ophthalmol 2013;61(3):95-9
   PubMedGoogle Scholar
• Kimura I, Shinoda K, Tanino T, et al. Effect of topical unoprostone isopropyl on optic nerve head circulation in controls and in normal-tension glaucoma patients. Jpn J Ophthalmol 2005;49(4):287-93
   PubMedGoogle Scholar
• EMA/COMP/318070/2013, C.f.O.M.P. Public summary of opinion on orphan designation: unoprostone isopropyl for the treatment of retinitis pigmentosa. European Medicines Agency; London, United Kingdom: 2013
   Google Scholar
• Martínez-Fernández de la Cámara C, Sequedo MD, Gómez-Pinedo U, et al. Phosphodiesterase inhibition induces retinal degeneration, oxidative stress and inflammation in cone-enriched cultures of porcine retina. Exp Eye Res 2013;111(0):122-33
   PubMedGoogle Scholar
• Wert KJ, Davis RJ, Sancho-Pelluz J, et al. Gene therapy provides long-term visual function in a pre-clinical model of retinitis pigmentosa. Hum Mol Genet 2013;22(3):558-67
   PubMedGoogle Scholar
• EMA/COMP/307456/2013, C.f.O.M.P. Public summary of opinion on orphan designation: adenovirus associated viral vector serotype 5 containing the human pde6β genefor the treatment of retinitis pigmentosa. European Medicines Agency; London, United Kingdom: 2013
   Google Scholar
• EMA/COMP/307446/2013, C.f.O.M.P. Public summary of opinion on orphan designation: expanded human allogeneic neural retinal progenitor cells extracted from neural retina for the treatment of retinitis pigmentosa. European Medicines Agency; London, United Kingdom: 2013
   Google Scholar
• EMA/COMP/272347/2013, C.f.O.M.P. Public summary of opinion on orphan designation: recombinant human nerve growth factor for the treatment of retinitis pigmentosa. European Medicines Agency; London, United Kingdom: 2013
   Google Scholar
• Chamcheu JC, Wood GS, Siddiqui IA, et al. Progress towards genetic and pharmacological therapies for keratin genodermatoses: current perspective and future promise. Exp Dermatol 2012;21(7):481-9
   PubMedGoogle Scholar
• Rev.1, C.f.O.M.P.E.C. Public summary of opinion on orphan designation: synthetic double-stranded siRNA oligonucleotide directed against the keratin 6a N171K mutation for the treatment of pachyonychia congenita. European Medicines Agency; London, United Kingdom: 2013
   Google Scholar
• Valstar M, Bruggenwirth H, Olmer R, et al. Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype. J Inherit Metab Dis 2010;33(6):759-67
   PubMedGoogle Scholar
• Fu H, DiRosario J, Kang L, et al. Restoration of central nervous system α-N-acetylglucosaminidase activity and therapeutic benefits in mucopolysaccharidosis IIIB mice by a single intracisternal recombinant adeno-associated viral type 2 vector delivery. J Gene Med 2010;12(7):624-33
   PubMedGoogle Scholar
• EMA/COMP/317797/2013, C.f.O.M.P. Public summary of opinion on orphan designation: recombinant human alpha-N-acetylglucosaminidase for the treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome). European Medicines Agency; London, United Kingdom: 2013
   Google Scholar
• EMA/COMP/277074/2013, C.f.O.M.P. Public summary of opinion on orphan designation: autologous CD34+ cells transduced with a lentiviral vector containing the human ADA gene for the treatment of adenosine-deaminase-deficient severe combined immunodeficiency. European Medicines Agency; London, United Kingdom: 2013
   Google Scholar
• Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med 2003;349(26):2527-39
   PubMed Web of Science ®Google Scholar
• Uchida K, Beck DC, Yamamoto T, et al. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med 2007;356(6):567-79
   PubMedGoogle Scholar
• Rev.1, C.f.O.M.P.E.C. EU/3/13/1147. Public summary of opinion on orphan designation: granulocyte-macrophage colony-stimulating factor for the treatment of pulmonary alveolar proteinosis. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2013/08/human_orphan_001233.jsp&mid=WC0b01ac058001d12b
   Google Scholar
• Anheim M, Tranchant C, Koenig M. The autosomal recessive cerebellar ataxias. N Engl J Med 2012;366(7):636-46
   PubMed Web of Science ®Google Scholar
• EMA/COMP/417562/2013, C.f.O.M.P. Dexamethasone sodium phosphate encapsulated in human autologous erythrocytes for the treatment of ataxia telangiectasia. European Medicines Agency; London, United Kingdom: 2013
   Google Scholar
• Menotta M, Biagiotti S, Bianchi M, et al. Dexamethasone partially rescues ataxia telangiectasia-mutated (ATM) deficiency in ataxia telangiectasia by promoting a shortened protein variant retaining kinase activity. J Biol Chem 2012;287(49):41352-63
   PubMedGoogle Scholar
• Erez A, Nagamani SC, Lee B. Argininosuccinate lyase deficiency-argininosuccinic aciduria and beyond. Am J Med Genet Part C Semin Med Genet 2011;157C(1):45-53
   PubMed Web of Science ®Google Scholar
• EMA/COMP/413216/2013, C.f.O.M.P. Public summary of opinion on orphan designation: heterologous human adult liver-derived progenitor cells for the treatment of argininosuccinic aciduria. European Medicines Agency; London, United Kingdom: 2013
   Google Scholar
• Crombez EA, Cederbaum SD. Hyperargininemia due to liver arginase deficiency. Mol Genet Metab 2005;84(3):243-51
   PubMed Web of Science ®Google Scholar
• EMA/COMP/413217/2013, C.f.O.M.P. Public summary of opinion on orphan designation: heterologous human adult liver-derived progenitor cells for the treatment of hyperargininemia. European Medicines Agency; London, United Kingdom: 2013
   Google Scholar
• Saheki T, Kobayashi K, Iijima M, et al. Adult-onset type II citrullinemia and idiopathic neonatal hepatitis caused by citrin deficiency: involvement of the aspartate glutamate carrier for urea synthesis and maintenance of the urea cycle. Mol Genet Metab 2004;81(Suppl):20-6
   Google Scholar
• Saheki T, Kobayashi K. Mitochondrial aspartate glutamate carrier (citrin) deficiency as the cause of adult-onset type II citrullinemia (CTLN2) and idiopathic neonatal hepatitis (NICCD). J Hum Genet 2002;47(7):333-41
   PubMedGoogle Scholar
• EMA/COMP/413220/2013, C.f.O.M.P. Public summary of opinion on orphan designation: heterologous human adult liver-derived progenitor cells for the treatment of citrullinemia type 2. European Medicines Agency; London, United Kingdom: 2013
   Google Scholar
• Camacho JA, Obie C, Biery B, et al. Hyperornithinaemia-hyperammonaemia-homocitrullinuria syndrome is caused by mutations in a gene encoding a mitochondrial ornithine transporter. Nat Genet 1999;22(2):151-8
   PubMedGoogle Scholar
• EMA/COMP/413224/2013, C.f.O.M.P. Public summary of opinion on orphan designation: heterologous human adult liver-derived progenitor cells for treatment of ornithine translocase deficiency. European Medicines Agency; London, United Kingdom: 2013
   Google Scholar
• Ahmad S. Concise review: limbal stem cell deficiency, dysfunction, and distress. Stem Cells Transl Med 2012;1(2):110-15
   PubMed Web of Science ®Google Scholar
• EMA/COMP/417565/2013, C.f.O.M.P. Public summary of opinion on orphan designation: ex vivo autologous human corneal epithelium containing stem cells for treatment of limbal stem cell deficiency. European Medicines Agency; London, United Kingdom: 2013
   Google Scholar
• Horie S. ADPKD: molecular characterization and quest for treatment. Clin Exp Nephrol 2005;9(4):282-91
   PubMedGoogle Scholar
• Torres VE, Meijer E, Bae KT, et al. Rationale and design of the TEMPO (Tolvaptan efficacy and safety in management of autosomal dominant polycystic kidney disease and its outcomes) 3-4 study. Am J Kidney Dis 2011;57(5):692-9
   PubMedGoogle Scholar
• EMA/COMP/444684/2013, C.f.O.M.P. Public summary of opinion on orphan designation: tolvaptan for the treatment of the autosomal dominant polycystic kidney disease. European Medicines Agency; London, United Kingdom: 2013
   Google Scholar
• Seamon J, Keller T, Saleh J, Cui Q. The pathogenesis of nontraumatic osteonecrosis. Arthritis 2012;2012:11
   Google Scholar
• Zhao D, Cui D, Wang B, et al. Treatment of early stage osteonecrosis of the femoral head with autologous implantation of bone marrow-derived and cultured mesenchymal stem cells. Bone 2012;50(1):325-30
   PubMed Web of Science ®Google Scholar
• Gangji V, Hauzeur J-P, Matos C, et al. Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells a pilot study. J Bone Joint Surg 2004;86(6):1153-60
   PubMedGoogle Scholar
• EMA/COMP/439952/2013, C.f.O.M.P. Public summary of opinion on orphan designation: human allogeneic bone marrow-derived osteoblastic-like cells for the treatment of non-traumatic osteonecrosis. European Medicines Agency; London, United Kingdom: 2013
   Google Scholar
• EMA/COMP/433918/2013, C.f.O.M.P. Public summary of opinion on orphan designation: budesonide for the treatment of eosinophilic eosphagitis. European Medicines Agency; London, United Kingdom: 2013
   Google Scholar
• Bains SN, Hsieh FH. Current approaches to the diagnosis and treatment of systemic mastocytosis. Ann Allergy Asthma Immunol 2010;104(1):1-10; quiz -2, 41
   PubMedGoogle Scholar
• EMA/COMP/439251/2013, C.f.O.M.P. Public summary of opinion on orphan designation: cladribine for the treatment of mastocytosis. European Medicines Agency; London, United Kingdom: 2013
   Google Scholar
• Jacob R, Zimmer K-P, Schmitz J, Naim HY. Congenital sucrase-isomaltase deficiency arising from cleavage and secretion of a mutant form of the enzyme. J Clin Invest 2000;106(2):281-7
   PubMed Web of Science ®Google Scholar
• EMA/COMP/440861/2013, C.f.O.M.P. Public summary of opinion on orphan designation: sacrosidase for the treatment of congenital sucrase isomaltase deficiency. European Medicines Agency; London, United Kingdom: 2013
   Google Scholar
• EMA/COMP/440861/2013, C.f.O.M.P. Public summary of opinion on orphan designation: eculizumab for neuromyelitis optica. European Medicines Agency; London, United Kingdom: 2013
   Google Scholar